王志菲，女，33岁，博士学历，专业方向：神经药理学。2002年华东师范大学 生物学 本科毕业，2007年中科院上海药物研究所 神经药理学 博士毕业。2008年至2014年，前往美国国立卫生研究院（NIH）担任访问****、研究员。2014年9月，上海中医药大学副研究员。
Neuropsychopharmacology, Journal of Cerebral Blood Flow & Metabolism, Neuropharmacology, Neurotheropeutics, PLOS ONE, Neuroscience Letters, Journal of the Neurological Sciences, Basic & Clinical Pharmacology & Toxicology, Acta Pharmacologica Sinica, Pharmaceutical Biology等国际期刊应邀审稿人。
研究方向：中药活性成分对脑中风等中枢神经系统疾病的表观遗传学治疗机理研究；中药活性成分预处理干细胞对脑中风等他神经退行性疾病治疗作用及机理研究。发表学术论文20多篇。
1.Leeds PR, Yu F, Wang Z, Chiu CT, Zhang Y, Leng Y, Linares GR, Chuang DM. A new avenue for lithium: intervention in traumatic brain injury. ACS Chemical Neuroscience. 2014 Apr 11. (Epub ahead of print)
2.Leng Y, Wang Z, Tsai LK, Leeds P, Fessler EB, Wang J, Chuang DM. FGF-21 is a novel target of mood stabilizing drugs and has a robust neuroprotective role. Molecular Psychiatry. 2014 Jan 28. (Epub ahead of print)
3.Chiu CT, Wang Z, Hunsberger JG, Chuang DM. Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacological Reviews. 2013, 65(1):105-42.
4.Yu F, Wang Z, Tanaka M, Chiu CT, Leeds P, Zhang Y, Chuang DM. Posttrauma cotreatment with lithium and valproate: reduction of lesion volume, attenuation of blood-brain barrier disruption, and improvement in motor coordination in mice with traumatic brain injury. Journal of Neurosurgery. 2013, 119(3):766-73.
5.Fessler EB, Chibane FL, Wang Z, Chuang DM. Potential roles of HDAC inhibitors in mitigating ischemia-induced brain damage and facilitating endogenous regeneration and recovery. Current Pharmaceutical Design. 2013, 19(28):5105-20.
6.Wang Z, Tsai LK, Munasinghe J, Leng Y, Fessler EB, Chibane F, Leeds P, Chuang DM. Chronic valproate treatment enhances post-ischemic angiogenesis and promotes functional recovery in a rat model of ischemic stroke. Stroke. 2012, 43(9):2430-6.
7.Hunsberger JG, Fessler EB, Wang Z, Elkahloun AG, Chuang DM. Post-insult valproic acid-regulated microRNAs: potential targets for cerebral ischemia. American Journal of Translational Research. 2012, 4(3):316-32.
8.Yu F, Wang Z, Tchantchou F, Chiu CT, Zhang Y, Chuang DM. Lithium ameliorates neurodegeneration, suppresses neuroinflammation, and improves behavioral performance in a mouse model of traumatic brain injury. Journal of Neurotrauma. 2012, 29(2):362-74.
9.Wang Z, Leng Y, Tsai LK, Leeds P, Chuang DM. Valproic acid attenuates blood-brain barrier disruption in a rat model of transient focal cerebral ischemia: roles of histone deacetylase and MMP-9 inhibition. Journal of Cerebral Blood Flow and Metabolism. 2011, 31(1):52-7.
10.Wang Z, Fessler E, Chuang DM. Beneficial effects of mood stabilizers lithium, valproate and lamotrigine in experimental stroke models. Acta Pharmacologica Sinica. 2011, 32(12):1433-45.
11.Tsai LK*, Wang Z*, Munasinghe J, Leng Y, Leeds P, Chuang DM. Mesenchymal stem cells primed with valproate and lithium robustly migrate to infarcted
regions and facilitate recovery in a stroke model. Stroke. 2011, 42(10):2932-9. (*Co-first author)
12.Chuang DM, Wang Z, Chiu CT. GSK-3 as a target for lithium-induced neuroprotection against excitotoxicity in neuronal cultures and animal models of ischemic stroke. Frontiers in Molecular Neuroscience. 2011, 4:15.
13.Omata N, Chiu CS, Moya PR, Leng Y, Wang Z, Leeds P, Hunsburg J, Chuang DM. Lentivirally mediated GSK-3β silencing in the hippocampal dentate gyrus induces antidepressant-like effects in stressed mice. International Journal of Neuropsychopharmacology. 2011, 14(5):711-7.
14.Tsai LK, Leng Y, Wang Z, Leeds P, Chuang DM. The mood stabilizers valproic acid and lithium enhance mesenchymal stem cell migration via distinct mechanisms. Neuropsychopharmacology. 2010, 35(11):2225-37.
15.Zhang HY, Zheng CY, Yan H, Wang ZF, Tang LL, Gao X, Tang XC. Potential therapeutic targets of huperzine A for Alzheimer's disease and vascular dementia. Chemico-Biological Interactions. 2008, 175(1-3):396-402.
16.Wang ZF, Wang J, Zhang HY, Tang XC. Huperzine A exhibits anti-inflammatory and neuroprotective effects in a rat model of transient focal cerebral ischemia. Journal of Neurochemistry. 2008, 106(4):1594-603.
17.Wang ZF, Yan J, Fu Y, Tang XC, Feng S, He XC, Bai DL. Pharmacodynamic study of FS-0311: a novel highly potent, selective acetylcholinesterase inhibitor. Cellular Molecular Neurobiology. 2008, 28(2):245-61.
18.Wang ZF, Tang XC. Huperzine A protects C6 rat glioma cells against oxygen-glucose deprivation-induced injury. FEBS Letters. 2007, 581(4):596-602.
19.He XC, Feng S, Wang ZF, Shi Y, Zheng S, Xia Y, Jiang H, Tang XC, Bai D. Study on dual-site inhibitors of acetylcholinesterase: Highly potent derivatives of bis- and bifunctional huperzine B. Bioorganic & Medicinal Chemistry. 2007, 15(3):1394-408.
20.Wang ZF, Tang LL, Yan H, Wang YJ, Tang XC. Effects of huperzine A on memory deficits and neurotrophic factors production after transient cerebral ischemia and reperfusion in mice. Pharmacology Biochemistry and Behavior. 2006, 83(4):603-11.
21.Feng S, Wang Z, He X, Zheng S, Xia Y, Jiang H, Tang X, Bai D. Bis-huperzine B: highly potent and selective acetylcholinesterase inhibitors. Journal of Medicinal Chemistry. 2005, 48(3):655-7.
22.Wang ZF, Zhou J, Tang XC. Huperzine B protects rat pheochromocytoma cells against oxygen-glucose deprivation-induced injury. Acta Pharmacologica Sinica. 2002, 23(12):1193-8.
23.王志菲，唐希灿。脑缺血损伤的炎症反应及治疗策略展望。 中国新药与临床杂志 2007 ; 26 ( 6 ): 454-461。
24.白东鲁，王志菲，冯松，唐希灿。石山碱的药理所用研究。《化学进展丛书——药物化学进展》，化学工业出版社，2005年。
电话：
Email: zfwang4911@163.com